Truist Lowers National Health Investors Price Target to $81 With 12.8% Upside
NHI•Truist Financial lowered NHI’s price target to $81 from $89, implying 12.78% upside from its $71.82 share price. The REIT holds a #4 Sell research rank while another analysis assigns a buy based on its 5% dividend yield, portfolio expansion and above-peer ROE driven by senior housing demand.
1. Price-Target Revision
On June 12, an analyst at Truist Financial trimmed the price target for National Health Investors to $81 from $89, reflecting a decrease of roughly 9%. With shares near $71.82 at the time, this adjustment implies a 12.78% upside potential.
2. Mixed Research Rankings
The REIT carries a #4 Sell rank in one major research ranking system, signaling a cautious earnings outlook. By contrast, a peer REIT holds a #1 Strong Buy rating, underscoring relative investor caution toward NHI’s near-term performance.
3. Bullish Yield and Portfolio Growth
A separate analysis assigns NHI a buy rating based on its attractive 5% dividend yield, recent portfolio expansion and resilient revenue streams. Rising demand for senior housing bolsters the outlook as experienced investors increase sector allocations.
4. Market Position and ROE Strength
With a market capitalization of about $3.48 billion, National Health Investors focuses on income-producing senior housing and medical facilities. The company’s above-peer return on equity highlights efficient use of shareholder investments to generate profit.
